Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova in High CV Risk Patients with Hypertriglyceridemia (STRENGTH)

A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients With Hypertriglyceridemia (STRENGTH)

The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of major adverse cardiac event outcomes is reached.

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.

Fields marked with an * are required

Newsletter

Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434